Citigroup
INKT icon

Citigroup’s MiNK Therapeutics INKT Stock Holding History

Citigroup’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-91
Closed -$958 – 5983
2026
Q1 		$958 Sell
91
-246
-73% -$2.74K ﹤0.01% 5486
2025
Q4 		$3.76K Buy
+337
New +$4.35K ﹤0.01% 5325
2022
Q3 		– Sell
-2
Closed – – 6067
2022
Q2 		$0 Sell
2
-6
-75% -$113 ﹤0.01% 6425
2022
Q1 		$0 Sell
8
-83
-91% -$2.49K ﹤0.01% 6463
2021
Q4 		$4K Buy
+91
New +$10.8K ﹤0.01% 5678

Other funds holding INKT

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DnB Asset Management
DnB Asset Management Oslo, Norway $35.7B AUM 27.58% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return

Citigroup's INKT Position: Q2 2026 in Review

Citigroup sold out of MiNK Therapeutics (INKT) in Q2 2026, closing a stake of 91 shares — an estimated $958 sold.

Citigroup first reported a position in INKT in Q4 2021 and held it in 5 quarters. The position peaked at $4K in Q4 2021. 27 funds tracked by Wall St. Rank hold INKT as of Q2 2026.

  • Citigroup reported no remaining MiNK Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Citigroup sold 91 MiNK Therapeutics shares in Q2 2026, an estimated $958.
  • Citigroup first reported a position in MiNK Therapeutics in Q4 2021 and held it in 5 quarters.
  • Citigroup's MiNK Therapeutics position peaked at $4K in Q4 2021.
  • 27 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.